Access to Normal Human Immunoglobulin in Australia
Outlined below is the national policy position on access, supply and use of normal human immunoglobulin (NHIg) under the national blood arrangements. This policy should be read in conjunction with the Council of Australian Governments (COAG) Health Council (former Standing Council on Health (SCoH)) Criteria for the clinical use of intravenous immunoglobulin in Australia Second Edition 2012.
NHIg may be supplied under the national blood arrangements for two purposes, as follows:
- NHIg may be supplied for public health disease control activities, to treat susceptible contacts of an indicated infectious disease (hepatitis A, measles, poliomyelitis or rubella), where directed by the public health units in each state and territory. Advice and guidance to public health units in responding to a notifiable disease event can be found in the Series of National Guidelines (SoNGs) at:http://www.health.gov.au/internet/main/publishing.nsf/Content/cdnasongs.htm.
- NHIg may be supplied for the treatment of immunodeficiency conditions for which the product is indicated, for patients for whom treatment with IVIg and SCIg (where available) are both contraindicated, provided that:
- the diagnosis and written prescription is provided by a relevant specialist clinician
- the same diagnostic, qualifying, exclusion and review criteria and authorisation process for the relevant conditions are used to authorise the supply of NHIg, as would apply for the supply of intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) for those conditions
- at the time of seeking authorisation, the prescribing specialist clinician confirms in writing the specific clinical reason why treatment with IVIg and SCIg are both contraindicated
- the governing requirements for SCIg are applied where NHIg is proposed to be used outside of the hospital setting, and
- ongoing access to supply of NHIg may cease if the required review and supporting documentation demonstrating clinical effectiveness against the review criteria have not been met.
NHIg will not be routinely provided for any other purpose, including travel prophylaxis for hepatitis A. Advice in relation to prophylaxis for hepatitis A can be found in The Australian Immunisation Handbook available at:http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home.
To order NHIg for public health disease post-exposure prophylaxis, please complete and lodge the relevant form below. On opening the form, please select your state or territory to populate the relevant contact details. If you print the forms before selecting your state or territory or are unable to use the drop down list to populate the contact details in the Normal Human Immunoglobulin order form, please see the document below to find the relevant contact details.
- Contact Details – Normal Human Immunoglobulin (NHIg) order form (pdf) (352.54 KB)
- Contact Details – Normal Human Immunoglobulin (NHIg) order form (docx) (51.6 KB)
Normal human immunoglobulin (NHIg) order form
For further information please contact the National Blood Authority on 13 000 IG GOV (13 000 44 468) or email IgGovernance@blood.gov.au.